EP0650367A1 - Blocage des interactions intercellulaires avec des molecules chimeriques cd43 - Google Patents
Blocage des interactions intercellulaires avec des molecules chimeriques cd43Info
- Publication number
- EP0650367A1 EP0650367A1 EP93913851A EP93913851A EP0650367A1 EP 0650367 A1 EP0650367 A1 EP 0650367A1 EP 93913851 A EP93913851 A EP 93913851A EP 93913851 A EP93913851 A EP 93913851A EP 0650367 A1 EP0650367 A1 EP 0650367A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell
- molecule
- cell targeting
- targeting molecule
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70542—CD106
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- a negatively charged CD43 extracellular domain may be fused to the receptors VCAM-1 and ICAM-l to produce chimeric proteins CD43:VCAM-1 and CD43:ICAM-l; such proteins bind and coat the surface of certain types of leukocytes, blocking interaction with their endothelial counterreceptors and therefore the intracellular interaction between the immune cells and the endothelium which leads to inflammation.
- the cotransfected cells were screened by immunofluorescence for CD43 expression, using an anti-CD43 monoclonal antibody, termed anti-Leu 22 (Becton Dickinson, Lincoln Park, NJ) . All CD43-positive HeLa cell clones selected by this method consistently expressed CD43 for the duration of the experiments (>6 mo) .
- CD43 A notable feature of CD43 is its extensive substitution with negatively charged, sialic acid residues (Remold et al., J . Biol . Chem . 261:7526, 1986; Carlsson et al., J . Biol . Chem . 261:12779, 1986). It has been proposed that these sialic acid residues confer an anti-adhesion function to CD43 by providing a net negative charge to cell surfaces, resulting in repulsion between CD43-positive cells (Brown et al., Nature (London) 289:456-460, 1981) .
- CD43 Two distinctive features of CD43 are the extensive O-glycosylation and sialylation of its extracellular domain (Remod-O'Donnell et al., J. Biol . Chem . 261:7526- 7530, 1986; Carlsson et al., J. Biol . Chem . 261:12779- 12786, 1986; Pallant et al., Proc . Natl . Acad . Sci . USA 86:1328-1332, 1989; Shelly et al., Proc . Natl . Acad . Sci . USA 86:2819-2823, 1989).
- the CD43 domain is not only negatively charged but also of sufficient size to physically interfere with the intercellular interaction.
- the CD43 domain includes the N-terminal 180 amino acids and, more preferably, includes the N-terminal 220-233 amino acids of the CD43 sequence (as described, e.g., in Shelley et al., Proc . Natl . Acad . Sci . USA 86:2819, 1989; Pallant et al., Proc. Natl . Acad . Sci . USA 86:1328, 1989).
- the cell targeting molecule can be chosen from ligands, receptors, counterreceptors, antibodies, carbohydrates, or any molecule which is capable of specific interaction with a surface molecule on the targeted cell.
- the cell targeting domain must also be soluble and, in addition, must be of sufficient size and composition to direct specific interaction with its binding partner on the target cell surface.
- the cell targeting domain preferably includes between the N-terminal 430 and N-terminal 452 amino acids of the ICAM-l sequence described by Staunton et al. (Cell 52:925, 1988);
- VCAM-1 the cell targeting domain preferably includes between the N-terminal 580 and the N- terminal 606 amino acids of the VCAM-1 sequence described by Osborn et al.
- CD43:LNF III, CD43:sialyl Lewis x , CD43:ICAM-1, and CD43:VCAM-1 therapeutic proteins are particularly useful for blocking interactions between white blood cells and activated endothelium and are therefore useful for treating or preventing inflammatory disorders, for example, the vasculitis disorders, lupus and rheumatoid arthritis, as well as for suppressing downstream immune responses leading, for example, to organ rejection.
- CD43:ICAM-l may also be used to disrupt cell-mediated, organ-specific inflammation secondary to virus infection thus could be useful for treating disorders such as viral myocarditis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89157192A | 1992-06-01 | 1992-06-01 | |
US891571 | 1992-06-01 | ||
PCT/US1993/004517 WO1994000143A1 (fr) | 1992-06-01 | 1993-05-13 | Blocage des interactions intercellulaires avec des molecules chimeriques cd43 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0650367A1 true EP0650367A1 (fr) | 1995-05-03 |
EP0650367A4 EP0650367A4 (fr) | 1998-04-15 |
Family
ID=25398441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93913851A Withdrawn EP0650367A4 (fr) | 1992-06-01 | 1993-05-13 | Blocage des interactions intercellulaires avec des molecules chimeriques cd43. |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0650367A4 (fr) |
JP (1) | JPH07507278A (fr) |
WO (1) | WO1994000143A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646248A (en) | 1993-06-08 | 1997-07-08 | La Jolla Cancer Research Foundation | E-selection binding soluble lamp-1 polypeptide |
US5980034A (en) * | 1996-03-11 | 1999-11-09 | Videojet Systems International, Inc. | Cross flow nozzle system for an ink jet printer |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
WO2008093166A2 (fr) * | 2006-05-11 | 2008-08-07 | Ghent University | Compositions associées à la sialoadhésine et procédés correspondants |
JP6765968B2 (ja) | 2014-04-10 | 2020-10-07 | シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート | 薬物制御による導入遺伝子の発現 |
CA2994829A1 (fr) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Cellules t porteuses de car bispecifiques pour le ciblage de tumeur solide |
WO2018111763A1 (fr) | 2016-12-12 | 2018-06-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Variants du facteur de transcription chimérique ayant une sensibilité accrue à l'induction de ligand de médicament d'expression transgénique dans des cellules de mammifère |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0391088A2 (fr) * | 1989-03-16 | 1990-10-10 | Center For Blood Research Laboratories, Inc. | Utilisation de dérivés fonctionnels de la molécule d'adhésion intercellulaire ICAM-1 dans une thérapie anti-virale |
WO1992005188A1 (fr) * | 1990-09-14 | 1992-04-02 | Biogen, Inc. | Production de glycoproteines multimeres par couplage chimique |
-
1993
- 1993-05-13 WO PCT/US1993/004517 patent/WO1994000143A1/fr not_active Application Discontinuation
- 1993-05-13 EP EP93913851A patent/EP0650367A4/fr not_active Withdrawn
- 1993-05-13 JP JP5519683A patent/JPH07507278A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0391088A2 (fr) * | 1989-03-16 | 1990-10-10 | Center For Blood Research Laboratories, Inc. | Utilisation de dérivés fonctionnels de la molécule d'adhésion intercellulaire ICAM-1 dans une thérapie anti-virale |
WO1992005188A1 (fr) * | 1990-09-14 | 1992-04-02 | Biogen, Inc. | Production de glycoproteines multimeres par couplage chimique |
Non-Patent Citations (4)
Title |
---|
See also references of WO9400143A1 * |
SHELLEY ET AL.: "MOLECULAR CHARACTERIZATION OF SIALOPHORIN (CD43), THE LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN DEFECTIVE IN WISKOTT-ALDRICH SYNDROME" PNAS, vol. 86, 1989, pages 2819-2823, XP002052839 * |
STAUNTON ET AL.: "THE ARRANGEMENT OF THE IMMUNOGLOBULIN-LIKE DOMAINS OF ICAM-1 AND THE BINDING SITES FOR LFA-1 AND RHINOVIRUS" CELL, vol. 61, April 1990, pages 243-254, XP002052841 * |
STOOLMAN: "ADHESION MOLECULES CONTROLLING LYMPHOCYTE MIGRATION" CELL, vol. 56, 1989, pages 907-910, XP002052840 * |
Also Published As
Publication number | Publication date |
---|---|
JPH07507278A (ja) | 1995-08-10 |
EP0650367A4 (fr) | 1998-04-15 |
WO1994000143A1 (fr) | 1994-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schwartz et al. | Identification of surface proteins mediating adherence of CD11/CD18-deficient lymphoblastoid cells to cultured human endothelium. | |
EP0408859B1 (fr) | Anticorps monoclonaux contre cellules endothéliales activées | |
DK175491B1 (da) | Anvendelse af ICAM-1 og dets funktionelle derivater til behandling af ikke-specifik inflammation | |
EP0488061B1 (fr) | Le site de liaison d'ICAM-1 pour Mac-1 | |
US5858981A (en) | Method of inhibiting phagocytosis | |
AU697488B2 (en) | Functionally active selectin-derived peptides and ligand for GMP-140 | |
HU214247B (hu) | Eljárás sejtközi adhéziós molekula ICAM-2 és kötőligandjai előállítására | |
Rich et al. | Role of alpha 5 beta 1 integrin in TGF-beta 1-costimulated CD8+ T cell growth and apoptosis. | |
US5648465A (en) | Cloning and expression of neurocan, a chondroitin sulfate proteoglycan | |
EP0650367A1 (fr) | Blocage des interactions intercellulaires avec des molecules chimeriques cd43 | |
AU701919B2 (en) | Methods of inhibiting phagocytosis | |
US6630313B2 (en) | Phosphatidyl serine receptors and uses thereof | |
AU723595B2 (en) | Methods of inhibiting phagocytosis | |
Root | Leukocyte adhesion proteins: their role in neutrophil function. | |
EP0505749A2 (fr) | Anticorps monoclonaux dirigés contre des cellules endothéliales activées et leurs applications thérapeutiques et diagnostiques | |
US5580780A (en) | Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies | |
US7399847B1 (en) | Nucleic acids encoding artificial P-selectin ligands | |
CA2191577C (fr) | Procede de traitement et de prevention de l'arteriosclerose | |
US6027922A (en) | Human foam cells and methods for preparing them, monoclonal antibodies to said foam cells and their pharmaceutical and diagnostic use | |
AU651633B2 (en) | The Mac-1 binding site of ICAM-1 | |
Brown et al. | Macrophage and inflammatory cell matrix receptors: LFA-1, MAC-1, p150, 95 family | |
WO1993005814A1 (fr) | Inhibition competitive des interactions entre lymphocytes t et b | |
Tchilian | Functional analysis of myeloid cell antigens | |
Greene | Studies on the ligand binding specificity and function of the rat Kupffer cell receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19941229 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RHK1 | Main classification (correction) |
Ipc: A61K 38/00 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19980227 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19980518 |